Emraclidine is under clinical development by Cerevel Therapeutics and currently in Phase I for Dementia Associated With Alzheimer’s Disease. According to GlobalData, Phase I drugs for Dementia Associated With Alzheimer’s Disease have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Emraclidine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Emraclidine overview

Emraclidine (CVL-231) is under development for the treatment of schizophrenia experiencing an acute exacerbation of psychosis, dementia associated with Alzheimer's disease (AD) and Alzheimer’s disease psychosis (psychosis). The drug candidate acts by targeting muscarinic acetylcholine receptor M4. The drug candidate is a positive allosteric modulator, or PAM. It is administered through oral route as tablets.

It was also under development for the treatment of Alzheimer’s disease.

Cerevel Therapeutics overview

Cerevel Therapeutics (Cerevel) is a clinical-stage biopharmaceutical company that develops therapies to treat neuroscience diseases. The company’s product pipeline includes various drug candidates such as Emraclidine for treatment of schizophrenia and Alzheimer’s disease psychosis; and Darigabat to treat epilepsy and panic disorder. Cerevel’s pipeline also includes Tavapadon drug candidate for treatment of both early-and late-stage Parkinson’s disease; and CVL-871 to treat dementia-related apathy. The company is also developing other programs such as CVL-354, PDE4 inhibitor, and M4 Agonist for therapeutic areas of major depressive disorder (MDD), psychiatric, neuroinflammatory disorder, and neurological indications. Cerevel is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Emraclidine’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.